TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Purpose: The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the impact of TP53 mutations in CLL. Patients and Methods: We assessed TP53 mutations by denaturing high-performance liquid chromatography (exons 2 to 11) in a randomized prospective trial (n = 375) with a follow-up of 52.8 months (German CLL Study Group CLL4 trial; fludarabine [F] v F + cyclophosphamide [FC]). Results: We found TP53 mutations in 8.5% of patients (28 of 328 patients). None of the patients with TP53 mutation showed a complete response. In patients with TP53 mutation, compared with patients without TP53 mutation, median progression-free survival (PFS; 23.3 v 62.2 months, respectively) and overall survival (OS; 29.2 v 84.6 months, respectively) were significantly decreased (both P < .001). TP53 mutations in the absence of 17p deletions were found in 4.5% of patients. PFS and OS for patients with 17p deletion and patients with TP53 mutation in the absence of 17p deletion were similar. Multivariate analysis identified TP53 mutation as the strongest prognostic marker regarding PFS (hazard ratio [HR] = 3.8; P < .001) and OS (HR = 7.2; P < .001). Other independent predictors of OS were IGHV mutation status (HR = 1.9), 11q deletion (HR = 1.9), 17p deletion (HR = 2.3), and FC treatment arm (HR = 0.6). Conclusion: CLL with TP53 mutation carries a poor prognosis regardless of the presence of 17p deletion when treated with F-based chemotherapy. Thus, TP53 mutation analysis should be incorporated into the evaluation of patients with CLL before treatment initiation. Patients with TP53 mutation should be considered for alternative treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Self-citationUnmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,642
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
Poeta, M. L., Manola, J., Goldwasser, M. A., Forastiere, A., Benoit, N., Califano, J. A., Ridge, J. A., Goodwin, J., Kenady, D., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 817
Kröber, A., Seiler, T., Benner, A., Bullinger, L., Brückle, E., Lichter, P., Döhner, H., & Stilgenbauer, S. (2002) · Blood · doi:10.1182/blood.v100.4.1410.h81602001410_1410_1416 · Cited by 785
Self-citationDohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Self-citation
Cited by
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationFischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Self-citationSF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
(2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30029-8 · Cited by 672
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 634
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.019 · Cited by 585
Self-citationGene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Döhner, K., Bühler, A., Böttcher, S., Ritgen, M., Kneba, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-546150 · Cited by 516
Self-citationThompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
Emerging patterns of somatic mutations in cancer
Watson, I. R., Takahashi, K., Futreal, P. A., & Chin, L. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3539 · Cited by 491
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationEichhorst, B., Hallek, M., & Dreyling, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
Self-citationA high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
Hallek, M., Shanafelt, T. D., & Eichhorst, B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30422-7 · Cited by 370
Self-citationThe manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Rossi, D., Khiabanian, H., Spina, V., Ciardullo, C., Bruscaggin, A., Famà, R., Rasi, S., Monti, S., Deambrogi, C., De Paoli, L., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539726 · Cited by 338
Anderson, M. A., Deng, J., Seymour, J. F., Tam, C., Kim, S. Y., Fein, J., Yu, L., Brown, J. R., Westerman, D., Si, E. G., et al. (2016) · Blood · doi:10.1182/blood-2016-01-688796 · Cited by 316
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Fabbri, G., Khiabanian, H., Holmes, A. B., Wang, J., Messina, M., Mullighan, C. G., Pasqualucci, L., Rabadan, R., & Dalla-Favera, R. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131448 · Cited by 302
Rossi, D., Fangazio, M., Rasi, S., Vaisitti, T., Monti, S., Cresta, S., Chiaretti, S., Del Giudice, I., Fabbri, G., Bruscaggin, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395673 · Cited by 289
The molecular pathogenesis of chronic lymphocytic leukaemia
Fabbri, G., & Dalla-Favera, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.8 · Cited by 286
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., Brown, J., Lau, A., Pratt, G., et al. (2016) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 276
Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C. E., Richards, S. M., Catovsky, D., & Morgan, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0838 · Cited by 270
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Byrd, J. C., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-870238 · Cited by 245
Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., Fasan, A., & Haferlach, C. (2017) · Leukemia · doi:10.1038/leu.2016.263 · Cited by 242
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla-Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 242
O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., Keating, M., Mitra, S., Holes, L., Yu, A. S., et al. (2015) · Blood · doi:10.1182/blood-2015-03-630947 · Cited by 241
“Alkaline phosphatase, increased 22 (34) 0 (0) Sodium, decreased 19 (30) 2 (3)”
Scarfò, L., Ferreri, A. J. M., & Ghia, P. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.003 · Cited by 232
Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., et al. (2018) · Leukemia · doi:10.1038/s41375-017-0007-7 · Cited by 204
“However, TP53 mutations also occur in the absence of del(17p) in about 5% of untreated patients and are associated with a poor outcome, similar to the disease course observed in del(17p) CLL patients [6, 7].”
BackgroundResultSelf-citationJones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., Loscertales, J., Taylor, K., Vandenberghe, E., Wach, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30019-4 · Cited by 202
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed, C. M., Fisher, S. A., Nowak, A. K., Lake, R. A., & Lesterhuis, W. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960317 · Cited by 197
Clinical Outcomes of TP53 Mutations in Cancers
Robles, A. I., Jen, J., & Harris, C. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026294 · Cited by 78
Ali, D., Mohammad, D. K., Mujahed, H., Jonson‐Videsäter, K., Nore, B., Paul, C., & Lehmann, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14036 · Cited by 49
The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?
Ablain, J., Nasr, R., Bazarbachi, A., & de Thé, H. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0087 · Cited by 44
“Note that some of the progression events may be shared by very different leukemia subtypes, as demonstrated for Ras or P53 mutations, Myc gain, or FLT3 activation (11, 12).”
BackgroundHuun, J., Lønning, P. E., & Knappskog, S. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.26 · Cited by 27
Lanasa, M. C., Davis, P. H., Datto, M., Li, Z., Gockerman, J. P., Moore, J. O., DeCastro, C. M., Friedman, D. R., Diehl, L. F., Rehder, C., et al. (2012) · Leukemia & Lymphoma · doi:10.3109/10428194.2011.610012 · Cited by 16
Metadata
- Authors
- Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Häbe, S., Winkler, D., Bühler, A., Edelmann, J., Bergmann, M., Hopfinger, G., Hensel, M., Hallek, M., Döhner, H., & Stilgenbauer, S.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-10-10
- Volume
- 28
- Issue
- 29
- Pages
- 4473-4479
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113895281
- Cited by
- 617
- References
- 28
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.